Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08XPN
|
|||
| Former ID |
DIB009427
|
|||
| Drug Name |
mab 1-7F9
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 2 | [1], [2] | |
| Company |
CeMines
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MHC class I NK cell receptor 2DL1 (CD158A) | Target Info | . | [1], [2], [3] |
| MHC class I NK cell receptor 2DL2 (CD158b1) | Target Info | . | [1], [2], [3] | |
| MHC class I NK cell receptor 2DL3 (CD158b2) | Target Info | . | [1], [2], [3] | |
| KEGG Pathway | Antigen processing and presentation | |||
| Natural killer cell mediated cytotoxicity | ||||
| Graft-versus-host disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| WikiPathways | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. | |||
| REF 2 | Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 Sep 24;114(13):2667-77. | |||
| REF 3 | Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 September 24; 114(13): 2667-2677. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.